Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation.
Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels CC, Verhoog LC, van den Ouweland AM, Niermeijer MF, Brekelmans CT, Klijn JG. Meijers-Heijboer H, et al. Among authors: van putten wl, van geel b, van den ouweland am. N Engl J Med. 2001 Jul 19;345(3):159-64. doi: 10.1056/NEJM200107193450301. N Engl J Med. 2001. PMID: 11463009 Free article.
Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients.
Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, van den Ouweland A, van Geel B, Brekelmans CT, Klijn JG. Kriege M, et al. Breast Cancer Res Treat. 2008 Sep;111(2):303-11. doi: 10.1007/s10549-007-9781-7. Epub 2007 Oct 19. Breast Cancer Res Treat. 2008. PMID: 17952592
Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk.
Brekelmans CT, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, van Geel AA, Menke M, Verhoog LC, van den Ouweland A, Obdeijn IM, Klijn JG; Rotterdam Committee for Medical and Genetic Counseling. Brekelmans CT, et al. J Clin Oncol. 2001 Feb 15;19(4):924-30. doi: 10.1200/JCO.2001.19.4.924. J Clin Oncol. 2001. PMID: 11181654
Survival in hereditary breast cancer associated with germline mutations of BRCA2.
Verhoog LC, Brekelmans CT, Seynaeve C, Dahmen G, van Geel AN, Bartels CC, Tilanus-Linthorst MM, Wagner A, Devilee P, Halley DJ, van den Ouweland AM, Meijers-Heijboer EJ, Klijn JG. Verhoog LC, et al. Among authors: van den ouweland am, van geel an. J Clin Oncol. 1999 Nov;17(11):3396-402. doi: 10.1200/JCO.1999.17.11.3396. J Clin Oncol. 1999. PMID: 10550133
Psychological impact of receiving a BRCA1/BRCA2 test result.
Lodder L, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, van der Meer CA, van den Ouweland AM, Niermeijer MF. Lodder L, et al. Among authors: van den ouweland am, van der meer ca. Am J Med Genet. 2001 Jan 1;98(1):15-24. Am J Med Genet. 2001. PMID: 11426450
Large regional differences in the frequency of distinct BRCA1/BRCA2 mutations in 517 Dutch breast and/or ovarian cancer families.
Verhoog LC, van den Ouweland AM, Berns E, van Veghel-Plandsoen MM, van Staveren IL, Wagner A, Bartels CC, Tilanus-Linthorst MM, Devilee P, Seynaeve C, Halley DJ, Niermeijer MF, Klijn JG, Meijers-Heijboer H. Verhoog LC, et al. Among authors: van veghel plandsoen mm, van staveren il, van den ouweland am. Eur J Cancer. 2001 Nov;37(16):2082-90. doi: 10.1016/s0959-8049(01)00244-1. Eur J Cancer. 2001. PMID: 11597388
278 results